The Business Standard believes that the partnership to produce biosimilars between Pfizer and Biocon is just one that will start a landslide of partnerships for Big Pharma. They believe that many companies will turn to India for production for vaccines and biosimilars in particular. Biotech drugs resulting in close to $580 million in revenue in just India alone, and fast growth throughout the globe presents opportunities for Pharma companies and biotech producers to partner up and produce viable generics, vaccines and biosimilars. The Business Standard believes that Indian companies that have the potential to benefit the most from this are
Panacea Biotec, Reliance Life Sciences, Bharat Biotech, BV Corp and Serum Institute of India, beside drug majors such as Wockhardt, Dr Reddy's Laboratories, Intas Biopharmaceuticals and Lupin.
|
Share this article with your social network, just click below to share now!
|
|
|
The global synthetic biology market is supposed to reach $13.4 billion by 2019. A recent study from Transparency Market Research shows that...
Oren Levy from Karp Lab gave an excellent talk called “MSCs on Steriods” last month at Biotech Week Boston. Oren's research focus is &q...
If you blink you will most likely miss some major design, invention or discovery in the robotics industry. The future is definitely here, an...
No comments :
Post a Comment